Hikma Pharmaceuticals Plc Company Profile (LON:HIK)

About Hikma Pharmaceuticals Plc (LON:HIK)

Hikma Pharmaceuticals Plc logoHikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: LON:HIK
  • CUSIP: N/A
  • Web: www.hikma.com/
Capitalization:
  • Market Cap: £2.88 billion
  • Outstanding Shares: 240,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 1,184.95
  • 200 Day Moving Avg: GBX 1,491.98
  • 52 Week Range: GBX 1,101 - GBX 2,346
P/E:
  • Trailing P/E Ratio: 17.39
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £1.96 billion
  • Price / Sales: 1.47
  • Book Value: GBX 10.17 per share
  • Price / Book: 1.18
Dividend:
  • Dividend Yield: 1.4%
Profitability:
  • EBITDA: £451 million
  • Net Margins: 7.82%
  • Return on Equity: 5.69%
  • Return on Assets: 3.19%
Misc:
  • Average Volume: 879,722 shs.
 

Frequently Asked Questions for Hikma Pharmaceuticals Plc (LON:HIK)

What is Hikma Pharmaceuticals Plc's stock symbol?

Hikma Pharmaceuticals Plc trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals Plc pay dividends? What is the dividend yield for Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc announced a dividend on Wednesday, March 15th. Stockholders of record on Thursday, April 6th will be paid a dividend of GBX 0.22 per share on Thursday, May 25th. This represents a dividend yield of 0.78%. The ex-dividend date is Thursday, April 6th. This is a positive change from Hikma Pharmaceuticals Plc's previous dividend of $0.21. The official announcement can be seen at this link. View Hikma Pharmaceuticals Plc's Dividend History.

Where is Hikma Pharmaceuticals Plc's stock going? Where will Hikma Pharmaceuticals Plc's stock price be in 2017?

11 brokerages have issued 12 month price targets for Hikma Pharmaceuticals Plc's stock. Their predictions range from GBX 1,045 to GBX 2,431. On average, they expect Hikma Pharmaceuticals Plc's share price to reach GBX 1,551.45 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals Plc.

Who are some of Hikma Pharmaceuticals Plc's key competitors?

Who are Hikma Pharmaceuticals Plc's key executives?

Hikma Pharmaceuticals Plc's management team includes the folowing people:

  • Said Darwazah, Chairman of the Board, Chief Executive
  • Mazen Samih Talib Darwazah, Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets
  • Khalid Nabilsi, Chief Financial Officer
  • Brian Hoffman, President, West-Ward Pharmaceuticals
  • Michael Raya, Chief Executive Officer, West-Ward Pharmaceuticals
  • Majda Labadi, Corporate Vice President - Human Resources and Head of Operations, MENA
  • Riad Mishlawi, EU Vice President and Global Head - Injectables
  • Susan Ringdal, Vice President - Corporate Strategy and Investor Relations
  • Hussein Arkhagha, General Counsel
  • Bassam Wael Rushdi Kanaan, Chief Strategy and Corporate Development Officer

How do I buy Hikma Pharmaceuticals Plc stock?

Shares of Hikma Pharmaceuticals Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals Plc's stock price today?

One share of Hikma Pharmaceuticals Plc stock can currently be purchased for approximately GBX 1,198.


MarketBeat Community Rating for Hikma Pharmaceuticals Plc (LON HIK)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  577
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hikma Pharmaceuticals Plc (LON:HIK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.09)
Consensus Price Target: GBX 1,551.45
Consensus Price Target History for Hikma Pharmaceuticals Plc (LON:HIK)
Price Target History for Hikma Pharmaceuticals Plc (LON:HIK)
Analysts' Ratings History for Hikma Pharmaceuticals Plc (LON:HIK)
Show:
DateFirmActionRatingPrice TargetDetails
10/6/2017J P Morgan Chase & CoLower Price TargetNeutralGBX 1,500 -> GBX 1,250View Rating Details
8/29/2017Stifel NicolausDowngradeHoldGBX 2,300 -> GBX 1,320View Rating Details
8/25/2017Barclays PLCLower Price TargetOverweightGBX 2,200 -> GBX 1,500View Rating Details
8/24/2017Citigroup Inc.Reiterated RatingNeutralGBX 1,350View Rating Details
8/22/2017Goldman Sachs Group, Inc. (The)DowngradeNeutralGBX 2,600 -> GBX 1,310View Rating Details
8/21/2017Morgan StanleyDowngradeEqual weightGBX 1,600 -> GBX 1,350View Rating Details
8/21/2017Jefferies Group LLCLower Price TargetHoldGBX 1,390 -> GBX 1,045View Rating Details
8/17/2017Numis Securities LtdReiterated RatingAddGBX 1,560View Rating Details
8/17/2017Peel HuntReiterated RatingHoldGBX 2,150View Rating Details
7/4/2017HSBC Holdings plcReiterated RatingReduceGBX 1,800View Rating Details
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431View Rating Details
3/16/2016Panmure GordonUpgradeBuyGBX 2,120View Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Hikma Pharmaceuticals Plc (LON:HIK)
Current Year EPS Consensus Estimate: $1.07 EPS

Dividends

Dividend History by Quarter for Hikma Pharmaceuticals Plc (LON HIK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/15/2017€0.220.78%4/6/20174/6/20175/25/2017
3/11/2015€0.210.64%4/16/20154/16/20155/21/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Hikma Pharmaceuticals Plc (LON:HIK)
Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Ali Al-HusryInsiderBuy50,000GBX 1,790£895,000
12/16/2016Mazen DarwazahInsiderBuy90,730GBX 1,849£1,677,597.70
12/12/2016Ali Al-HusryInsiderBuy50,000GBX 1,707£853,500
12/9/2016Ali Al-HusryInsiderBuy50,000GBX 1,723£861,500
12/6/2016Ali Al-HusryInsiderBuy100,000GBX 1,682£1,682,000
12/5/2016Ali Al-HusryInsiderBuy50,000GBX 1,674£837,000
12/2/2016Mazen DarwazahInsiderBuy50,000GBX 1,662£831,000
12/1/2016Mazen DarwazahInsiderBuy50,000GBX 1,674£837,000
11/30/2016Said DarwazahInsiderBuy50,000GBX 1,662£831,000
9/28/2016Said DarwazahInsiderBuy10,000GBX 2,085£208,500
9/27/2016Ali Al-HusryInsiderBuy50,000GBX 2,094£1,047,000
9/26/2016Said DarwazahInsiderBuy50,000GBX 2,078£1,039,000
9/23/2016Ali Al-HusryInsiderBuy50,000GBX 2,099£1,049,500
9/21/2016Ali Al-HusryInsiderBuy50,000GBX 2,138£1,069,000
9/16/2016Al-Husry,AliInsiderBuy50,000GBX 2,119£1,059,500
9/15/2016Darwazah,SaidInsiderBuy70,251GBX 2,122£1,490,726.22
9/8/2016Darwazah,MazenInsiderBuy150,000GBX 2,162£3,243,000
9/6/2016Darwazah,MazenInsiderBuy155,991GBX 2,194£3,422,442.54
8/31/2016Al-Husry,AliInsiderBuy140,000GBX 2,150£3,010,000
8/26/2016Darwazah,SaidInsiderBuy200,000GBX 2,160£4,320,000
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hikma Pharmaceuticals Plc (LON:HIK)
Latest Headlines for Hikma Pharmaceuticals Plc (LON:HIK)
Source:
Loading headlines, please wait.

Social

Social activity is not available for this stock.

Chart

Hikma Pharmaceuticals Plc (HIK) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.